GW Pharma MS drug gets German approval

GW Pharmaceuticals has been given a lift after German authorities gave the thumbs up to its multiple sclerosis drug Sativex.

The firm, and its partner Almirall, claim Savitex can help treat moderate to severe spasticity in patients with MS.

The German drug regulators agree, although they say there is only "a minor added benefit".

Start your trial of MoneyWeek today

Get unparalleled financial insight, analysis and expert opinion you can profit from.

Start your trial

Sign up for MoneyWeek’s free twice-daily newsletter.

Join more than 165,000 subscribers and keep yourself informed with latest financial news, insights and expert analysis to help you understand what really matters when it comes to your finances.

Join more than 165,000 subscribers and keep yourself informed with latest financial news, insights and expert analysis to help you understand what really matters when it comes to your finances.

Sign up

"We are pleased by the positive decision of the G-BA, which recognises that Sativex has an important role to play in meeting the needs of patients with spasticity due to multiple sclerosism," said Farid Taha, Managing Director of Almirall Hermal GmbH.

"Whilst the G-BA has defined the benefit as minor, we believe that Sativex offers a substantial benefit to patients and we now look forward to the meeting with the pricing authorities as the next step in this process."

GW's stock was up 2.7% at 8:42.

BS